RecruitingPhase 2NCT07118241

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

Studying Primary Sjögren disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Lubris Bio Pty Ltd
Intervention
Recombinant Human Proteoglycan 4(drug)
Enrollment
80 enrolled
Eligibility
18-75 years · All sexes
Timeline
20252026

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07118241 on ClinicalTrials.gov

Other trials for Primary Sjögren disease

Additional recruiting or active studies for the same condition.

See all trials for Primary Sjögren disease

← Back to all trials